Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HER2/topoisomerase I inhibitor ADC GQ1005

An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated, via a cleavable open-ring linker, to a topoisomerase I (TopoI) inhibitor-based payload, with potential antineoplastic activity. Upon administration of the anti-HER2/topoisomerase I inhibitor ADC GQ1005, the anti-HER2 monoclonal antibody moiety targets and binds to HER2 expressed on tumor cells. Upon cellular uptake, the TopoI inhibitor inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication which results in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of HER2-expressing tumor cells. Also, GQ1005 induces an additional bystander effect, thereby further killing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADC GQ1005
anti-HER2 antibody-drug conjugate GQ1005
anti-HER2/TOP1i ADC GQ1005
Code name:GQ 1005
GQ-1005
GQ1005
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search